C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Global Market Report 2025
상품코드:1825693
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
CXC 케모카인 수용체 4(CXCR4) 길항제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.2%로 성장할 전망이며, 25억 3,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 HIV와 AIDS의 용도 확대, 줄기세포 동원에 대한 수요 증가, 자가면역 질환의 가능성, 바이오뱅크 구상의 성장, 창약에서 인공지능(AI)의 통합 등에 기인할 것으로 보입니다. 예측 기간 주요 동향으로는 희귀질병용 의약품 개발에 대한 주목의 고조, 병용요법의 개발, 정밀종양학적 접근의 채용, 신규요법의 임상시험 확대, 약물 전달 기술의 진보 등을 들 수 있습니다.
향후 5년간의 성장률 9.2%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 무역 마찰은 프랑스와 일본에서 개발된 프리릭서포와 관련된 동원 요법의 가격을 상승시켜 이식편의 회수가 지연되고 혈액내과의 치료비가 상승하여 미국의 줄기세포 이식을 방해할 수 있습니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.
인간 면역결핍 바이러스(HIV) 유병률 증가는 경련성 발성 장애 치료 시장의 성장을 가속할 것으로 예측됩니다. HIV는 CD4(T) 세포를 공격하여 면역계를 표적으로 하고 약화시키는 바이러스이며, 치료하지 않으면 에이즈로 이어질 수 있습니다. HIV의 확산이 증가하는 배경으로는 낮은 인지도, 의료 접근 제한, 높은 감염률 및 지역에 따라 예방이 충분하지 않을 수 있습니다. CXCR4 길항제는 CXCR4 수용체를 억제하여 HIV를 관리하고 바이러스가 면역 세포에 접근하고 감염되는 것을 방지합니다. 예를 들어, 유엔 합동 에이즈 계획(UNAIDS)에 따르면 2022년에는 세계에서 3,900만 명(3,310만-4,570만 명)의 HIV 감염자가 있어, 그 해의 신규 감염자는 130만 명(100만-170만 명)이었습니다. 그 결과 HIV의 유병률 증가가 CXCR4 길항제 시장 확대에 박차를 가하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 성장률 분석
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 실적 : 규모 및 성장(2019-2024년)
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
BL-8040
GMI-1359
프리릭사폴(AMD3100)
바릭사포르티드(POL6326)
USL311
브릭사폴(GPC-100)
기타 유형
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
오랄
주사제
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 제품 파이프라인별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
승인
임상시험
전임상
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
암
인간 면역결핍 바이러스(HIV)
만성 염증성 질환
줄기세포 동원
면역질환 및 자가면역질환
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : BL-8040 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
종양학에 대한 용도(백혈병, 림프종)
줄기세포 동원
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : GMI-1359 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
암 치료(유방암, 고형 종양)
골수 이식
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 프리릭서폴(AMD3100) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
조혈 줄기세포 동원
암 치료(다발성 골수종)
HIV 치료(HIV 저장소)
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 발릭사포르티드(POL6326) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
암 치료(고형 종양, 유방암)
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : USL311 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
줄기세포 동원
종양학에 대한 용도
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 브릭사폴(GPC-100) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
암 치료(림프종, 고형 종양)
줄기세포 동원
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 기타 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
실험적 또는 전임상적 CXCR4 길항제
CXCR4 길항제와의 병용 요법
제7장 지역별 및 국가별 분석
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 경쟁 구도
CXC 케모카인 수용체 4(CXCR4) 길항제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
GlaxoSmithKline
Eli Lilly and Company
Amgen Inc.
Takeda Chemical Industries Ltd.
Kyowa Kirin Co. Ltd.
BioLegend Inc.
Kura Oncology Inc.
CUSABIO TECHNOLOGY LLC
Cayman Chemical
X4 Pharmaceuticals Inc.
BioLineRx Ltd.
Spexis Ltd.
Biokine Therapeutics Ltd.
GlycoMimetics
AnorMED Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
CXC 케모카인 수용체 4(CXCR4) 길항제 시장(2029년) : 새로운 기회를 제공하는 국가
CXC 케모카인 수용체 4(CXCR4) 길항제 시장(2029년) : 새로운 기회를 제공하는 부문
CXC 케모카인 수용체 4(CXCR4) 길항제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
C-X-C chemokine receptor 4 (CXCR4) antagonists are pharmaceutical compounds aimed at inhibiting the CXCR4 receptor, which is found on the surface of specific cells. These antagonists function by blocking the interaction between CXCR4 and its ligand, CXCL12 (also known as SDF-1), a key player in cell migration, hematopoiesis, and immune responses.
The main types of CXCR4 antagonists include BL-8040, GMI-1359, plerixafor (AMD3100), balixafortide (POL6326), USL311, burixafor (GPC-100), and others. These antagonists can be administered orally or via injection. BL-8040, for example, is a synthetic peptide developed to block CXCR4, which is involved in cancer cell migration and survival. The product pipelines feature both approved clinical trials and pre-clinical trials for a range of applications, including cancer, human immunodeficiency virus (HIV), chronic inflammatory diseases, stem cell mobilization, and immune and autoimmune diseases. These products are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The C-X-C chemokine receptor 4 (CXCR4) antagonist market research report is one of a series of new reports from The Business Research Company that provides C-X-C chemokine receptor 4 (CXCR4) antagonist market statistics, including C-X-C chemokine receptor 4 (CXCR4) antagonist industry global market size, regional shares, competitors with a C-X-C chemokine receptor 4 (CXCR4) antagonist market share, detailed C-X-C chemokine receptor 4 (CXCR4) antagonist market segments, market trends and opportunities, and any further data you may need to thrive in the C-X-C chemokine receptor 4 (CXCR4) antagonist industry. This C-X-C chemokine receptor 4 (CXCR4) antagonist market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The c-x-c chemokine receptor 4 (cxcr4) antagonists market size has grown strongly in recent years. It will grow from $1.62 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increasing transparency in clinical trial data, patient-centric healthcare policies, rising prevalence of chemotherapy resistance, policies emphasizing patient-centered care and access, and increasing preference for targeted therapies.
The c-x-c chemokine receptor 4 (cxcr4) antagonists market size is expected to see strong growth in the next few years. It will grow to $2.53 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to expanding applications in HIV or AIDS, rising demand for stem cell mobilization, potential in autoimmune diseases, growth in biobanking initiatives, and integration of artificial intelligence (AI) in drug discovery. Major trends in the forecast period include increasing focus on orphan drug development, development of combination therapies, adoption of precision oncology approaches, expanding clinical trials for novel therapies, and advancements in drug delivery technologies.
The forecast of 9.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. stem cell transplantation by inflating prices of plerixafor and related mobilization therapies developed in France and Japan, resulting in delayed graft collections and higher hematology treatment expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rise in human immunodeficiency virus (HIV) prevalence is expected to drive growth in the spasmodic dysphonia treatment market. HIV, a virus that targets and weakens the immune system by attacking CD4 (T) cells, can lead to AIDS if untreated. The increasing prevalence of HIV is due to factors such as low awareness, limited healthcare access, high transmission rates, and inadequate prevention in some regions. CXCR4 antagonists help manage HIV by blocking the CXCR4 receptor, preventing the virus from accessing and infecting immune cells, thus aiding in controlling the virus and enhancing immune response. For instance, according to Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2022, there were 39 million [33.1 million-45.7 million] people living with HIV globally, with 1.3 million [1 million-1.7 million] new infections that year. Consequently, the growing prevalence of HIV is fueling the expansion of the CXCR4 antagonist market.
Leading companies in the CXCR4 antagonist market are focusing on developing bioequivalents to improve treatment options and patient outcomes for various diseases. Bioequivalents are pharmaceutical products that have similar bioavailability when compared under similar conditions. For example, in May 2024, Gland Pharma, an India-based generic injectable manufacturer, received approval from the United States Food and Drug Administration (US FDA) for Plerixafor Injection. This product is bioequivalent and therapeutically equivalent to the reference drug, MOZOBIL (plerixafor) injection by Genzyme Corporation. Plerixafor is a CXCR4 antagonist used in conjunction with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells into the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
In April 2024, PANTHERx, a US-based specialty pharmacy, partnered with X4 Pharmaceuticals Inc. to facilitate the distribution of XOLREMDI (mavorixafor). This oral treatment, taken once daily, selectively antagonizes the CXCR4 receptor and was approved by the U.S. Food and Drug Administration (FDA). It is the first FDA-approved therapy specifically indicated for patients aged 12 and older with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. X4 Pharmaceuticals Inc., a US-based late-stage clinical biopharmaceutical company, focuses on developing and commercializing novel therapeutics, including CXCR4 antagonists such as XOLREMDI (mavorixafor).
Major companies operating in the C-X-C chemokine receptor 4 (CXCR4) antagonists market are Pfizer Inc., F-Hoffmann La Roche Ltd., Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Takeda Chemical Industries Ltd., Kyowa Kirin Co. Ltd., BioLegend Inc., Kura Oncology Inc., CUSABIO TECHNOLOGY LLC, Cayman Chemical, X4 Pharmaceuticals Inc., BioLineRx Ltd., Spexis Ltd., Biokine Therapeutics Ltd., GlycoMimetics, AnorMED Inc., CohBar Inc.
North America was the largest region in the C-X-C chemokine receptor type 4 antagonists market in 2024. The regions covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The C-X-C chemokine receptor 4 (CXCR4) antagonist market consists of sales of TN14003 (Trogarzo), X4P-001 (Mavorixafor), TG-0054, and KRH-3955. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on c-x-c chemokine receptor 4 (cxcr4) antagonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for c-x-c chemokine receptor 4 (cxcr4) antagonists ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The c-x-c chemokine receptor 4 (cxcr4) antagonists market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: BL-8040; GMI-1359; Plerixafor (AMD3100); Balixafortide (POL6326); USL311; Burixafor (GPC-100); Other Types
2) By Route Of Administration: Oral; Injectable
3) By Product Pipeline: Approved; Clinical Trials; Pre-Clinical
4) By Application: Cancer; Human Immunodeficiency Virus (HIV); Chronic Inflammatory Disease; Stem Cell Mobilization; Immune And Autoimmune Diseases
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By BL-8040: Oncology Applications (Leukemia, Lymphoma); Stem Cell Mobilization
2) By GMI-1359: Cancer Treatment (Breast Cancer, Solid Tumors); Bone Marrow Mobilization
3) By Plerixafor (AMD3100): Hematopoietic Stem Cell Mobilization; Cancer Treatment (Multiple Myeloma); HIV Treatment (HIV Reservoirs)
4) By Balixafortide (POL6326): Cancer Treatment (Solid Tumors, Breast Cancer)
5) By USL311: Stem Cell Mobilization; Oncology Applications
6) By Burixafor (GPC-100): Cancer Treatment (Lymphoma, Solid Tumors); Stem Cell Mobilization
7) By Other Types: Experimental Or Preclinical CXCR4 Antagonists; Combination Therapies With CXCR4 Antagonists
Companies Mentioned: Pfizer Inc.; F-Hoffmann La Roche Ltd.; Sanofi; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline; Eli Lilly and Company; Amgen Inc.; Takeda Chemical Industries Ltd.; Kyowa Kirin Co. Ltd.; BioLegend Inc.; Kura Oncology Inc.; CUSABIO TECHNOLOGY LLC; Cayman Chemical; X4 Pharmaceuticals Inc.; BioLineRx Ltd.; Spexis Ltd.; Biokine Therapeutics Ltd.; GlycoMimetics; AnorMED Inc.; CohBar Inc.
4. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Growth Analysis And Strategic Analysis Framework
5.1. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.1. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BL-8040
GMI-1359
Plerixafor (AMD3100)
Balixafortide (POL6326)
USL311
Burixafor (GPC-100)
Other Types
6.2. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
6.3. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Approved
Clinical Trials
Pre-Clinical
6.4. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer
Human Immunodeficiency Virus (HIV)
Chronic Inflammatory Disease
Stem Cell Mobilization
Immune And Autoimmune Diseases
6.5. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.6. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of BL-8040, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology Applications (Leukemia, Lymphoma)
Stem Cell Mobilization
6.7. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of GMI-1359, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Treatment (Breast Cancer, Solid Tumors)
Bone Marrow Mobilization
6.8. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Plerixafor (AMD3100), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hematopoietic Stem Cell Mobilization
Cancer Treatment (Multiple Myeloma)
HIV Treatment (HIV Reservoirs)
6.9. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Balixafortide (POL6326), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Treatment (Solid Tumors, Breast Cancer)
6.10. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of USL311, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stem Cell Mobilization
Oncology Applications
6.11. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Burixafor (GPC-100), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Treatment (Lymphoma, Solid Tumors)
Stem Cell Mobilization
6.12. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Experimental Or Preclinical CXCR4 Antagonists
Combination Therapies With CXCR4 Antagonists
7. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Regional And Country Analysis
7.1. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
9.1. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
9.2. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
10.1. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
11.1. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
11.2. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
12.1. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
13.1. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
14.1. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
14.2. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
15.1. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
15.2. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
16.1. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.2. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
22.1. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
23.1. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
23.2. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
24.1. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
24.2. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
26.1. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
26.2. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
27.1. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
